MedKoo product information:

 Melphalan Hydrochloride

Melphalan is an orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Melphalan  is used to treat multiple myeloma and ovarian cancer, and occasionally malignant melanoma. The agent was first investigated as a possible drug for use in melanoma. It was not found to be effective, but has been found to be effective in the treatment of myeloma. Adminstration: oral or intravenous; dosing varies by purpose and route of administration as well as patient weight.

DRUG DESCRIPTION

Melphalan, also known as L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent that is active against selected human neoplastic diseases. It is known chemically as 4-[bis(2-chloroethyl)amino]-L-phenylalanine. The molecular formula is C13H18Cl2N2O2 and the molecular weight is 305.20. Melphalan is the active L-isomer of the compound and was first synthesized in 1953 by Bergel and Stock; the D-isomer, known as medphalan, is less active against certain animal tumors, and the dose needed to produce effects on chromosomes is larger than that required with the L-isomer. The racemic (DL-) form is known as merphalan or sarcolysin. Melphalan is practically insoluble in water and has a pKa1 of ~2.5. ALKERAN for Injection is supplied as a sterile, nonpyrogenic, freeze-dried powder. Each single-use vial contains melphalan hydrochloride equivalent to 50 mg melphalan and 20 mg povidone. ALKERAN for Injection is reconstituted using the sterile diluent provided. Each vial of sterile diluent contains sodium citrate 0.2 g, propylene glycol 6.0 mL, ethanol (96%) 0.52 mL, and Water for Injection to a total of 10 mL. ALKERAN for Injection is administered intravenously.

 1: Moriya K, Wakabayashi A, Shimizu M, Tamura H, Dan K, Takahashi H. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells. Cancer Immunol Immunother. 2010 Jul;59(7):1083-95. Epub 2010 Mar 10. PubMed PMID: 20221597; PubMed Central PMCID: PMC2860563.

2: Vasquez KM. Targeting and processing of site-specific DNA interstrand crosslinks. Environ Mol Mutagen. 2010 Mar 1. [Epub ahead of print] PubMed PMID: 20196133; PubMed Central PMCID: PMC2895014.

3: Karki SS, Hazare R, Kumar S, Bhadauria VS, Balzarini J, De Clercq E. Synthesis, anticancer and cytostatic activity of some 6H-indolo[2,3-b]quinoxalines. Acta Pharm. 2009 Dec;59(4):431-40. PubMed PMID: 19919932.

4: Youssef D, Potter E, Jha M, De Clercq E, Balzarini J, Stables JP, Jha A. Design, synthesis and bioevaluation of novel maleamic amino acid ester conjugates of 3,5-bisarylmethylene-4-piperidones as cytostatic agents. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6364-7. Epub 2009 Sep 22. PubMed PMID: 19819135.

5: Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009 Dec;11(12):1579-86. Epub 2009 Oct 3. Review. PubMed PMID: 19801562.

6: Ouédraogo M, De Maesschalck E, Soentjens-Werts V, Dubois J. In vitro cytotoxicity study of oxaziridines generated after chlordiazepoxide, demoxepam, and desmethylchlordiazepoxide UV irradiation. Drug Chem Toxicol. 2009;32(4):417-23. PubMed PMID: 19793035.

7: Mezencev R, Kutschy P, Salayova A, Updegrove T, McDonald JF. The design, synthesis and anticancer activity of new nitrogen mustard derivatives of natural indole phytoalexin 1-methoxyspirobrassinol. Neoplasma. 2009;56(4):321-30. PubMed PMID: 19473057.

8: McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM 3rd. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res. 2009 Jun;7(6):897-906. Epub 2009 May 26. PubMed PMID: 19470598; PubMed Central PMCID: PMC2745049.

9: Mori A, Hada K, Kato T, Hiraishi Y, Maeda T, Tanaka Y, Niimi H, Mizuno K, Ikeda Y, Sekido I, Kimura K, Nakamura Y, Saito H, Hasegawa S. [A project of the 6th chapter of the Oncology Research Group, Aichi Prefectural Society of Hospital Pharmacists: an attempt to make a pamphlet for patients undergoing LEED therapy, based on analysis of complications]. Gan To Kagaku Ryoho. 2009 May;36(5):893-7. Japanese. PubMed PMID: 19461202.

10: Dierickx KM, Journé F, Gerbaux P, Morandini R, Kauffmann JM, Ghanem GE. Improving the spectrophotometric determination of the alkylating activity of anticancer agents: a new insight into the mechanism of the NBP method. Talanta. 2009 Feb 15;77(4):1370-5. Epub 2008 Sep 18. PubMed PMID: 19084651.

11: Shukla G, Tiwari AK, Kumar N, Sinha D, Mishra P, Chandra H, Mishra AK. Polyethylene glycol conjugates of methotrexate and melphalan: synthesis, radiolabeling and biologic studies. Cancer Biother Radiopharm. 2008 Oct;23(5):571-9. PubMed PMID: 18999930.

12: Bielawski K, Bielawska A. Small-molecule based delivery systems for alkylating antineoplastic compounds. ChemMedChem. 2008 Apr;3(4):536-42. Review. PubMed PMID: 18157855.

13: Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell. 2007 Oct 19;131(2):257-70. PubMed PMID: 17956728.

14: Stanchev S, Momekov G, Jensen F, Manolov I. Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives. Eur J Med Chem. 2008 Apr;43(4):694-706. Epub 2007 May 27. PubMed PMID: 17614164.

15: Testart-Paillet D, Girard P, You B, Freyer G, Pobel C, Tranchand B. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit Rev Oncol Hematol. 2007 Jul;63(1):1-11. Epub 2007 Apr 5. Review. PubMed PMID: 17418588.

16: Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther. 2007 Mar;6(3):886-97. PubMed PMID: 17363483.

17: Bracht K, Liebeke M, Ritter CA, Grünert R, Bednarski PJ. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. Anticancer Drugs. 2007 Apr;18(4):389-404. PubMed PMID: 17351391.

18: Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J Pharmacol Exp Ther. 2007 Jun;321(3):1109-17. Epub 2007 Mar 9. PubMed PMID: 17351106.

19: Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial. In Vivo. 2006 Nov-Dec;20(6A):715-8. PubMed PMID: 17203752.

20: Wang XJ, Hayes JD, Wolf CR. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res. 2006 Nov 15;66(22):10983-94. PubMed PMID: 17108137.

21: Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nüssler V, Hasmann M. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res. 2006 Aug 30;11(8):313-21. PubMed PMID: 17052966.

22: Johansson K, Ahlen K, Rinaldi R, Sahlander K, Siritantikorn A, Morgenstern R. Microsomal glutathione transferase 1 in anticancer drug resistance. Carcinogenesis. 2007 Feb;28(2):465-70. Epub 2006 Aug 18. PubMed PMID: 16920737.

23: Mougenot P, Bressolle F, Culine S, Solassol I, Poujol S, Pinguet F. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer. Anticancer Res. 2006 May-Jun;26(3B):2197-203. PubMed PMID: 16821586.

24: Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006 Jun 1;107(11):4223-33. Epub 2006 Feb 21. Review. PubMed PMID: 16493006.

25: Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, Orelli BJ, Bishop DK, Hirano S, Ohzeki M, Ishiai M, Yamamoto K, Takata M, Arakawa H, Buerstedde JM, Yamazoe M, Kawamoto T, Araki K, Takahashi JA, Hashimoto N, Takeda S, Sonoda E. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 2005 Dec 15;65(24):11704-11. PubMed PMID: 16357182.

26: Dutta S, Abe H, Aoyagi S, Kibayashi C, Gates KS. DNA damage by fasicularin. J Am Chem Soc. 2005 Nov 2;127(43):15004-5. PubMed PMID: 16248621.

27: Witte AB, Anestål K, Jerremalm E, Ehrsson H, Arnér ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005 Sep 1;39(5):696-703. PubMed PMID: 16085187.

28: Rickardson L, Fryknäs M, Dhar S, Lövborg H, Gullbo J, Rydåker M, Nygren P, Gustafsson MG, Larsson R, Isaksson A. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer. 2005 Aug 22;93(4):483-92. PubMed PMID: 16012520; PubMed Central PMCID: PMC2361589.

29: Sawada K, Noda K, Nakajima H, Shimbara N, Furuichi Y, Sugimoto M. Differential cytotoxicity of anticancer agents in pre- and post-immortal lymphoblastoid cell lines. Biol Pharm Bull. 2005 Jul;28(7):1202-7. PubMed PMID: 15997098.

30: Wong P, Lee C, Tannock IF. Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells. Clin Cancer Res. 2005 May 1;11(9):3553-7. PubMed PMID: 15867259.

31: Mittal S, Song X, Vig BS, Landowski CP, Kim I, Hilfinger JM, Amidon GL. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs. Mol Pharm. 2005 Jan-Feb;2(1):37-46. PubMed PMID: 15804176.

32: Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 2005 Jun 15;105(12):4759-66. Epub 2005 Feb 22. PubMed PMID: 15728126; PubMed Central PMCID: PMC1895008.

33: Krych M. [Acute renal failure]. Internist (Berl). 2005 Jan;46(1):30-8. Review. German. PubMed PMID: 15580461.

34: Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res. 2004 Oct 1;10(19):6476-86. PubMed PMID: 15475435.

35: Gould KA, Nixon C, Tilby MJ. p53 elevation in relation to levels and cytotoxicity of mono- and bifunctional melphalan-DNA adducts. Mol Pharmacol. 2004 Nov;66(5):1301-9. Epub 2004 Aug 12. PubMed PMID: 15308759.

36: Dimmock JR, Chamankhah M, Das U, Zello GA, Quail JW, Yang J, Nienaber KH, Sharma RK, Selvakumar P, Balzarini J, De Clercq E, Stables JP. Cytotoxic and topographical properties of 6-arylidene-2-dimethylaminomethylcyclohexanone hydrochlorides and related compounds. J Enzyme Inhib Med Chem. 2004 Feb;19(1):1-10. PubMed PMID: 15202487.

37: Heinis C, Alessi P, Neri D. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. Biochemistry. 2004 May 25;43(20):6293-303. PubMed PMID: 15147213.

38: Deng HB, Adikari M, Parekh HK, Simpkins H. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol. 2004 Oct;54(4):301-7. Epub 2004 May 11. PubMed PMID: 15138708.

39: Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004 Mar;56(1):53-102. Review. PubMed PMID: 15001663.

40: Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003 Dec;33(12):601-7. Review. PubMed PMID: 14769836.

41: Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 2004 Jan 15;64(2):565-71. PubMed PMID: 14744770.

42: Goto H, Yang B, Petersen D, Pepper KA, Alfaro PA, Kohn DB, Reynolds CP. Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines. Mol Cancer Ther. 2003 Sep;2(9):911-7. PubMed PMID: 14555710.

43: Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood. 2003 Dec 15;102(13):4384-92. Epub 2003 Aug 21. PubMed PMID: 12933583.

44: Nakajima T, Takayama T, Miyanishi K, Nobuoka A, Hayashi T, Abe T, Kato J, Sakon K, Naniwa Y, Tanabe H, Niitsu Y. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. J Pharmacol Exp Ther. 2003 Sep;306(3):861-9. Epub 2003 Jun 12. PubMed PMID: 12805482.

45: Jönsson-Videsäter K, Andersson G, Bergh J, Paul C. Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicin. Ther Drug Monit. 2003 Jun;25(3):331-9. PubMed PMID: 12766562.

46: Kumar R, Lown JW. Recent developments in novel pyrrolo[2,1-c][1,4]benzodiazepine conjugates: synthesis and biological evaluation. Mini Rev Med Chem. 2003 Jun;3(4):323-39. Review. PubMed PMID: 12678826.

47: Donepudi M, Jovasevic VM, Raychaudhuri P, Mokyr MB. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunol Immunother. 2003 Mar;52(3):162-70. Epub 2003 Feb 6. PubMed PMID: 12649745.

48: Rapp M, Giraud I, Maurizis JC, Galmier MJ, Madelmont JC. Synthesis and in vivo biodisposition of [14C]-quaternary ammonium-melphalan conjugate, a potential cartilage-targeted alkylating drug. Bioconjug Chem. 2003 Mar-Apr;14(2):500-6. PubMed PMID: 12643763.

49: Uneda S, Hata H, Matsuno F, Nagasaki A, Harada N, Mitsuya Y, Matsuzaki H, Mitsuya H. A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br J Haematol. 2003 Feb;120(3):396-404. PubMed PMID: 12580953.

50: Jones RB. Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Cancer Treat Res. 2002;112:305-22. Review. PubMed PMID: 12481722.

51: Dimmock JR, Padmanilyam MP, Zello GA, Quail JW, Oloo EO, Prisciak JS, Kraatz HB, Cherkasov A, Lee JS, Allen TM, Santos CL, Manavathu EK, De Clercq E, Balzarini J, Stables JP. Cytotoxic 1,3-diarylidene-2-tetralones and related compounds. Eur J Med Chem. 2002 Oct;37(10):813-24. PubMed PMID: 12446039.

52: Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P, Hequet O, Espinouse D, Salles G, Roy P, Eljaafari-Corbin A, Du Manoir-Baumgarten C, Coiffier B. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2002 Dec;30(11):769-75. PubMed PMID: 12439700.

53: Gul HI, Gul M, Erciyas E. Syntheses and stability studies of some Mannich bases of acetophenones and evaluation of their cytotoxicity against Jurkat cells. Arzneimittelforschung. 2002;52(8):628-35. PubMed PMID: 12236052.

54: Frost BM, Lönnerholm G, Nygren P, Larsson R, Lindhagen E. In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia. Anticancer Drugs. 2002 Aug;13(7):735-42. PubMed PMID: 12187330.

55: Nakamoto T, Inagawa H, Nishizawa T, Honda T, Kanou J, Nagasue N, Soma G. Antitumor effects of isolated hypoxic hepatic perfusion (IHHP) with high-dose TNF against colonic liver metastases in a rat model. Anticancer Res. 2002 Jul-Aug;22(4):2455-9. PubMed PMID: 12174943.

56: Wildiers H, Guetens G, de Boeck G, Landuyt W, Verbeken E, Highley M, de Bruijn EA, van Oosterom AT. Melphalan availability in hypoxia-inducible factor-1alpha+/+ and factor-1alpha-/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport. Int J Cancer. 2002 Jun 1;99(4):514-9. PubMed PMID: 11992540.

57: Giraud I, Rapp M, Maurizis JC, Madelmont JC. Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma. J Med Chem. 2002 May 9;45(10):2116-9. PubMed PMID: 11985479.

58: Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol. 2002 Apr 1;63(7):1219-28. PubMed PMID: 11960598.

59: Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, Battaglia R, Howard M, D'Incalci M, Broggini M. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res. 2002 Apr 15;62(8):2332-6. PubMed PMID: 11956092.

60: Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol. 2001 Dec;28(6):607-12. Review. PubMed PMID: 11740818.

61: Lejeune FJ, Kroon BB, Di Filippo F, Hoekstra HJ, Santinami M, Liénard D, Eggermont AM. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am. 2001 Oct;10(4):821-32, ix. Review. PubMed PMID: 11641093.

62: Jiang JD, Zhang H, Li JN, Roboz J, Qiao WB, Holland JF, Bekesi G. High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) in vivo. Anticancer Res. 2001 May-Jun;21(3B):1681-9. PubMed PMID: 11497247.

63: Pinguet F, Savelli K, Petit I, Gerbi-Benmansour Y, Fabbro M. Pharmaco-economic study of intensive chemotherapy with peripheral blood progenitor cell support for advanced breast cancer. Oncol Rep. 2001 Sep-Oct;8(5):1013-7. PubMed PMID: 11496307.

64: Ben-Efraim S. Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr Drug Targets. 2001 Jun;2(2):197-212. Review. PubMed PMID: 11469719.

65: Nieto Y. Pharmacodynamics of high-dose chemotherapy. Curr Drug Metab. 2001 Mar;2(1):53-66. Review. PubMed PMID: 11465151.

66: Vashishtha SC, Allen TM, Halleran S, Szydlowski J, Santos CL, De Clercq E, Balzarani J, Dimmock JR. Cytotoxic and anticancer properties of some 4-aryl-3-arylcarbonyl-1-ethyl-4-piperidinols and related compounds. Pharmazie. 2001 May;56(5):390-3. PubMed PMID: 11400554.

67: Jin G, You Y, Ahn B. Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1473-6. PubMed PMID: 11378380.

68: Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res. 2001 May;7(5):1438-45. PubMed PMID: 11350915.

69: Gharat L, Taneja R, Weerapreeyakul N, Rege B, Polli J, Chikhale PJ. Targeted drug delivery systems 6: Intracellular bioreductive activation, uptake and transport of an anticancer drug delivery system across intestinal Caco-2 cell monolayers. Int J Pharm. 2001 May 21;219(1-2):1-10. PubMed PMID: 11337161.

70: Finch RA, Shyam K, Penketh PG, Sartorelli AC. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res. 2001 Apr 1;61(7):3033-8. PubMed PMID: 11306484.

71: Marchini S, Damia G, Broggini M, Pennella G, Ripamonti M, Marsiglio A, Geroni C. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res. 2001 Mar 1;61(5):1991-5. PubMed PMID: 11280757.

72: Keyes KA, Segovia JC, Bueren JA, Parchment RE, Albella B. Latent hematopoietic stem cell toxicity associated with protracted drug administration. Exp Hematol. 2001 Mar;29(3):286-94. PubMed PMID: 11274755.

73: Carystinos GD, Alaoui-Jamali MA, Phipps J, Yen L, Batist G. Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells. Cancer Chemother Pharmacol. 2001;47(2):126-32. PubMed PMID: 11269738.

74: Killian DM, Chikhale PJ. A bioreversible prodrug approach designed to shift mechanism of brain uptake for amino-acid-containing anticancer agents. J Neurochem. 2001 Feb;76(4):966-74. PubMed PMID: 11181816.

75: Dimmock JR, Padmanilayam MP, Puthucode RN, Nazarali AJ, Motaganahalli NL, Zello GA, Quail JW, Oloo EO, Kraatz HB, Prisciak JS, Allen TM, Santos CL, Balzarini J, De Clercq E, Manavathu EK. A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues. J Med Chem. 2001 Feb 15;44(4):586-93. PubMed PMID: 11170648.

76: Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, Dimopoulos MA, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N, Maniatis A. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group. Eur J Haematol. 2001 Jan;66(1):18-23. PubMed PMID: 11168503.

77: Paumi CM, Ledford BG, Smitherman PK, Townsend AJ, Morrow CS. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J Biol Chem. 2001 Mar 16;276(11):7952-6. Epub 2000 Dec 13. PubMed PMID: 11115505.

78: Horikoshi N, Saotome T, Yoshida N, Aiba K. [Oral cancer chemotherapy in the clinic]. Gan To Kagaku Ryoho. 2000 Oct;27(11):1641-6. Review. Japanese. PubMed PMID: 11057313.

79: Oosthuizen MM, Nel MJ, Greyling D. Heat shock treated oesophageal cancer cells become thermosensitized against anticancer drugs. Anticancer Res. 2000 Jul-Aug;20(4):2697-703. PubMed PMID: 10953346.

80: Killian DM, Gharat L, Chikhale PJ. Modulating blood-brain barrier interactions of amino acid-based anticancer agents. Drug Deliv. 2000 Jan-Mar;7(1):21-5. PubMed PMID: 10895416.

81: Keyes KA, Albella B, LoRusso PM, Bueren JA, Parchment RE. Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clin Cancer Res. 2000 Jun;6(6):2474-81. PubMed PMID: 10873102.

82: Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol. 2000 Jun 15;164(12):6230-6. PubMed PMID: 10843675.

83: Ghielmini M, Bosshard G, Pampallona S, Genini D, Bernier J, Sessa C. Differential toxicity of anticancer drugs on late (GM-CFC) and early (LTC-IC) hemopoietic progenitors in vitro. Cell Biol Toxicol. 1999;15(6):395-404. PubMed PMID: 10811535.

84: Pinguet F, Bressolle F, Culine S, Fabbro M, Astre C, Chevillard C. Influence of the schedule of exposure on the cytotoxic effect of melphalan on human 8226 and A2780 cells. Eur J Cancer. 1999 Sep;35(9):1402-6. PubMed PMID: 10658534.

85: Filipits M, Drach J, Pohl G, Schuster J, Stranzl T, Ackermann J, Königsberg R, Kaufmann H, Gisslinger H, Huber H, Ludwig H, Pirker R. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res. 1999 Sep;5(9):2426-30. PubMed PMID: 10499614.

86: Vahrmeijer AL, van Dierendonck JH, Schutrups J, van de Velde CJ, Mulder GJ. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery. Cancer Chemother Pharmacol. 1999;44(2):111-6. PubMed PMID: 10412944.

87: Benoit L, Duvillard C, L'Helgouarc'h JL, Chauffert B. [Intratumoral chemotherapy in an experimental animal model: another therapeutic possibility in cancerology]. Presse Med. 1999 Mar 20;28(11):571-6. French. PubMed PMID: 10214376.

88: Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs. 1998 Dec;56(6):1019-38. Review. PubMed PMID: 9878990.

89: Dimmock JR, Vashishtha SC, Patil SA, Udupa N, Dinesh SB, Devi PU, Kamath R. Cytotoxic and anticancer activities of some 1-aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides. Pharmazie. 1998 Oct;53(10):702-6. PubMed PMID: 9812337.

90: Kraut EH, Ju R, Muller M. The use of topoisomerase I inhibitors in multiple myeloma. Semin Hematol. 1998 Jul;35(3 Suppl 4):32-8. Review. PubMed PMID: 9779880.

91: Canitrot Y, Cazaux C, Fréchet M, Bouayadi K, Lesca C, Salles B, Hoffmann JS. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12586-90. PubMed PMID: 9770529; PubMed Central PMCID: PMC22874.

92: Medlicott NJ, Foster KA, Audus KL, Gupta S, Stella VJ. Comparison of the effects of potential parenteral vehicles for poorly water soluble anticancer drugs (organic cosolvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC). J Pharm Sci. 1998 Sep;87(9):1138-43. PubMed PMID: 9724567.

93: Niitsu Y, Takahashi Y, Ban N, Takayama T, Saito T, Katahira T, Umetsu Y, Nakajima T, Ohi M, Kuga T, Sakamaki S, Matsunaga T, Hirayama Y, Kuroda H, Homma H, Kato J, Kogawa K. A proof of glutathione S-transferase-pi-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chem Biol Interact. 1998 Apr 24;111-112:325-32. PubMed PMID: 9679563.

94: Marinelli A, Vahrmeijer AL, van de Velde CJ. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res. 1998;147:83-94. Review. PubMed PMID: 9670271.

95: Vashishtha SC, Nazarali AJ, Dimmock JR. Application of fluorescence microscopy to measure apoptosis in Jurkat T cells after treatment with a new investigational anticancer agent (N.C.1213). Cell Mol Neurobiol. 1998 Aug;18(4):437-45. PubMed PMID: 9619299.

96: Okazaki Y, Miura N, Satoh M, Imura N, Naganuma A. Metallothionein-mediated resistance to multiple drugs can be induced by several anticancer drugs in mice. Biochem Biophys Res Commun. 1998 Apr 28;245(3):815-8. PubMed PMID: 9588197.

97: Chen X, Schecter RL, Griffith OW, Hayward MA, Alpert LC, Batist G. Characterization of 5-oxo-L-prolinase in normal and tumor tissues of humans and rats: a potential new target for biochemical modulation of glutathione. Clin Cancer Res. 1998 Jan;4(1):131-8. PubMed PMID: 9516961.

98: Vodovozova EL, Gayenko GP, Razinkov VI, Korchagina EY, Bovin NV, Molotkovsky JG. Saccharide-assisted delivery of cytotoxic liposomes to human malignant cells. Biochem Mol Biol Int. 1998 Mar;44(3):543-53. PubMed PMID: 9556216.

99: Vahrmeijer AL, Van Der Eb MM, Van Dierendonck JH, Kuppen PJ, Van De Velde CJ. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin Surg Oncol. 1998 Apr-May;14(3):262-8. Review. PubMed PMID: 9548610.

100: Manusama ER, Nooijen PT, Ten Hagen TL, Van Der Veen AH, De Vries MW, De Wilt JH, Van Ijken MG, Marquet RL, Eggermont AM. Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program. Semin Surg Oncol. 1998 Apr-May;14(3):232-7. PubMed PMID: 9548606.

101: Kerr DE, Li Z, Siemers NO, Senter PD, Vrudhula VM. Development and activities of a new melphalan prodrug designed for tumor-selective activation. Bioconjug Chem. 1998 Mar-Apr;9(2):255-9. PubMed PMID: 9548542.

102: Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96. PubMed PMID: 9392620.

103: Laurençot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer. 1997 Sep 17;72(6):1021-6. PubMed PMID: 9378536.

104: Saito T, Ikeda S, Hisai H, Katahira T, Kondo H, Takahashi Y, Takayama T. [Glutathione levels in human colon cancer cell line M7609 following culture in a low sulfur amino acid medium and its sensitivity to various anticancer drugs]. Gan To Kagaku Ryoho. 1997 May;24(7):823-7. Japanese. PubMed PMID: 9170520.

105: Babaian IuS, Khudaverdian NV, Karapetian LG, Kazarian RS, Sogomonian LR. [Comparative study of three antineoplastic alkylating agents on DNA]. Biofizika. 1997 Mar-Apr;42(2):542-3. Russian. PubMed PMID: 9172701.

106: Cappella P, Onado C, Sena G, Montalenti F, Spinelli L, Ubezio P. Time- and dose-dependence of DNA fragmentation induced by anticancer agents: a flow cytometric study. Eur J Histochem. 1997;41 Suppl 2:67-8. PubMed PMID: 9859787.

107: Rekha GK, Sladek NE. Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother Pharmacol. 1997;40(3):215-24. PubMed PMID: 9219504.

108: Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 1997;39(6):541-6. PubMed PMID: 9118467.

109: Watts ME, Woodcock M, Arnold S, Chaplin DJ. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res. 1997 Jan-Feb;17(1A):71-5. PubMed PMID: 9066632.

110: Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996 Dec 24;52(12):1855-65. PubMed PMID: 8951344.

111: Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5. PubMed PMID: 8968230; PubMed Central PMCID: PMC1235474.

112: Eggermont AM, Schraffordt Koops H, Liénard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996 Oct;14(10):2653-65. PubMed PMID: 8874324.

113: Teicher BA, Chen YN, Ara G, Emi Y, Kakeji Y, Maehara Y, Keyes S, Northey D. Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma. Int J Cancer. 1996 Sep 17;67(6):864-70. PubMed PMID: 8824560.

114: Rashid G, Ophir R, Pecht M, Lourie S, Meshorer A, Ben-Efraim S, Trainin N, Burstein Y, Keisari Y. Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy. J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):324-33. PubMed PMID: 8941872.

115: Ben-Efraim S. Cancer immunotherapy: hopes and pitfalls: a review. Anticancer Res. 1996 Sep-Oct;16(5B):3235-40. Review. PubMed PMID: 8920797.

116: Witt KL, Bishop JB. Mutagenicity of anticancer drugs in mammalian germ cells. Mutat Res. 1996 Aug 17;355(1-2):209-34. Review. PubMed PMID: 8781584.

117: Zervas K, Pouli A, Perifanis V, Papanastasiou K, Chatziyianni M, Mitsouli C, Maniatis A. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. Eur J Haematol. 1996 Aug;57(2):142-8. PubMed PMID: 8856091.

118: Liu B, Cvijic ME, Jetzt A, Chin KV. Cisplatin resistance and regulation of DNA repair in cAMP-dependent protein kinase mutants. Cell Growth Differ. 1996 Aug;7(8):1105-12. PubMed PMID: 8853907.

119: Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S, Niitsu Y. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 1996 Aug 1;56(15):3577-82. PubMed PMID: 8758929.

120: Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 1996 Jun 5;88(11):734-41. PubMed PMID: 8637027.

121: Ophir R, Pecht M, Keisari Y, Rashid G, Lourie S, Meshorer A, Ben-Efraim S, Trainin N, Burstein Y. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy. Immunopharmacol Immunotoxicol. 1996 May;18(2):209-36. PubMed PMID: 8771368.

122: Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996 Mar 1;56(5):988-94. PubMed PMID: 8640791.

123: Muckenschnabel I, Bernhardt G, Spruss T, Buschauer A. Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice. Cancer Chemother Pharmacol. 1996;38(1):88-94. PubMed PMID: 8603457.

124: Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995 Oct;13(10):2567-74. PubMed PMID: 7595708.

125: Nakagawa I, Nishi E, Naganuma A, Imura N. Effect of preinduction of metallothionein synthesis on clastogenicity of anticancer drugs in mice. Mutat Res. 1995 Sep;348(1):37-43. PubMed PMID: 7565913.

126: Tilby MJ, McCartney H, Cordell J, Frank AJ, Dean CJ. A monoclonal antibody that recognizes alkali-stabilized melphalan-DNA adducts and its application in immunofluorescence microscopy. Carcinogenesis. 1995 Aug;16(8):1895-901. PubMed PMID: 7634420.

127: Kondo Y, Woo ES, Michalska AE, Choo KH, Lazo JS. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res. 1995 May 15;55(10):2021-3. PubMed PMID: 7743495.

128: Teicher BA, Holden SA, Ara G, Dupuis NP, Goff D. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. Cancer J Sci Am. 1995 May-Jun;1(1):43-8. PubMed PMID: 9166453.

129: Yu X, Wu Z, Fenselau C. Covalent sequestration of melphalan by metallothionein and selective alkylation of cysteines. Biochemistry. 1995 Mar 14;34(10):3377-85. PubMed PMID: 7880833.

130: Pauwels O, Atassi G, Kiss R. Combination of computerized morphonuclear and multivariate analyses to characterize in vitro the antineoplastic effect of alkylating agents. J Pharmacol Toxicol Methods. 1995 Feb;33(1):35-45. PubMed PMID: 7727807.

131: Lunel-Orsini C, Buttin G, De Saint Vincent BR. A glutathione depletion selectively imposed on mu glutathione S-transferase overproducing cells increases nitrogen mustard toxicity. Biochem Pharmacol. 1995 Jan 31;49(3):329-38. PubMed PMID: 7857320.

132: Chelvi TP, Jain SK, Ralhan R. Hyperthermia-mediated targeted delivery of thermosensitive liposome-encapsulated melphalan in murine tumors. Oncol Res. 1995;7(7-8):393-8. PubMed PMID: 8747602.

133: Teicher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res. 1995;7(5):237-43. PubMed PMID: 8534929.

134: Teicher BA, Menon K, Northey D, Liu J, Kufe DW, Kaddurah-Daouk R. Cyclocreatine in cancer chemotherapy. Cancer Chemother Pharmacol. 1995;35(5):411-6. PubMed PMID: 7850923.

135: Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res. 1994 Oct 15;54(20):5255-7. PubMed PMID: 7923149.

136: Chapman RS, Whetton AD, Dive C. The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase. Cancer Res. 1994 Oct 1;54(19):5131-7. PubMed PMID: 7923130.

137: Bunting KD, Lindahl R, Townsend AJ. Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J Biol Chem. 1994 Sep 16;269(37):23197-203. PubMed PMID: 8083225.

138: Fujii R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M, Kuwano M, Akiyama S. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res. 1994 Apr;85(4):426-33. PubMed PMID: 8200854.

139: Weiskirch LM, Bar-Dagan Y, Mokyr MB. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol Immunother. 1994 Apr;38(4):215-24. PubMed PMID: 8168116.

140: Jansen M, Dykstra M, Lee JI, Stables J, Topley P, Knick VC, Mullin RJ, Duch DS, Smith GK. Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression. Biochem Pharmacol. 1994 Mar 15;47(6):1067-78. PubMed PMID: 8147906.

141: Houghton PJ, Cheshire PJ, Hallman JC 3rd, Gross JL, McRipley RJ, Sun JH, Behrens CH, Dexter DL, Houghton JA. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemother Pharmacol. 1994;33(4):265-72. PubMed PMID: 8281618.

142: Teicher BA, Schwartz JL, Holden SA, Ara G, Northey D. In vivo modulation of several anticancer agents by beta-carotene. Cancer Chemother Pharmacol. 1994;34(3):235-41. PubMed PMID: 8004757.

143: Teicher BA. Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy. Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1109-20. Review. PubMed PMID: 7849913.

144: Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993 Nov 1;53(21):5225-32. PubMed PMID: 8106143.

145: Satoh M, Kondo Y, Mita M, Nakagawa I, Naganuma A, Imura N. Prevention of carcinogenicity of anticancer drugs by metallothionein induction. Cancer Res. 1993 Oct 15;53(20):4767-8. PubMed PMID: 8402657.

146: Slavik M, Wu J, Riley C. Salivary excretion of anticancer drugs. Ann N Y Acad Sci. 1993 Sep 20;694:319-21. PubMed PMID: 8215078.

147: Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 1993 Sep-Oct;13(5A):1549-56. PubMed PMID: 8239534.

148: Vrudhula VM, Senter PD, Fischer KJ, Wallace PM. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J Med Chem. 1993 Apr 2;36(7):919-23. PubMed PMID: 8464046.

149: Lejeune FJ, Liénard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer. 1993;29A(4):606-12. Review. PubMed PMID: 8435217.

150: Shklar G, Schwartz J. Oral cancer inhibition by micronutrients. The experimental basis for clinical trials. Eur J Cancer B Oral Oncol. 1993 Jan;29B(1):9-16. Review. PubMed PMID: 8180584.

151: Dimanche-Boitrel MT, Garrido C, Chauffert B. Kinetic resistance to anticancer agents. Cytotechnology. 1993;12(1-3):347-56. Review. PubMed PMID: 7764456.

152: Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992 Dec 1;52(23):6702-4. PubMed PMID: 1384969.

153: Janáky T, Juhász A, Rékási Z, Serfözö P, Pinski J, Bokser L, Srkalovic G, Milovanovic S, Redding TW, Halmos G, et al. Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10203-7. PubMed PMID: 1332035; PubMed Central PMCID: PMC50306.

154: Colangelo D, Guo HY, Connors KM, Kubota T, Silvestro L, Hoffman RM. Correlation of drug response in human tumors histocultured in vitro with an image-analysis MTT end point and in vivo xenografted in nude mice. Anticancer Res. 1992 Sep-Oct;12(5):1373-6. PubMed PMID: 1444193.

155: Dorr RT, Alberts DS. Topical absorption and inactivation of cytotoxic anticancer agents in vitro. Cancer. 1992 Aug 15;70(4 Suppl):983-7. PubMed PMID: 1638468.

156: Takada Y, Vistica DT, Greig NH, Purdon D, Rapoport SI, Smith QR. Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res. 1992 Apr 15;52(8):2191-6. PubMed PMID: 1559223.

157: Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res. 1992 Apr 1;52(7):1710-6. PubMed PMID: 1312897.

158: Janáky T, Juhász A, Bajusz S, Csernus V, Srkalovic G, Bokser L, Milovanovic S, Redding TW, Rékási Z, Nagy A, et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):972-6. PubMed PMID: 1310542; PubMed Central PMCID: PMC48367.

159: Teicher BA, Holden SA, Ara G, Ha CS, Herman TS, Northey D. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents. J Cancer Res Clin Oncol. 1992;118(7):509-14. PubMed PMID: 1624542.

160: Sotomayor EA, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, Frei E 3rd. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol. 1992;30(5):377-84. PubMed PMID: 1505076.

161: Holden SA, Teicher BA, Ha C, Ara G, Herman TS. Enhancement by perflusion emulsion (Oxygent) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents. Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):895-8. PubMed PMID: 1391529.

162: Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 1992;31(2):205-13. Review. PubMed PMID: 1352455.

163: Ayash L, Korbut T, Herman TS, Teicher BA. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells. Cancer Lett. 1991 Dec 9;61(1):7-14. PubMed PMID: 1764699.

164: Caldecott K, Jeggo P. Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat Res. 1991 Sep;255(2):111-21. PubMed PMID: 1922147.

165: Cummings J, MacLellan A, Smyth JF, Farmer PB. Determination of reactive nitrogen mustard anticancer drugs in plasma by high-performance liquid chromatography using derivatization. Anal Chem. 1991 Aug 1;63(15):1514-9. PubMed PMID: 1952082.

166: Lazo JS, Basu A. Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. Semin Cancer Biol. 1991 Aug;2(4):267-71. Review. PubMed PMID: 1912530.

167: Niimi S, Yokoyama S, Terashima Y, Saijo N. [Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes]. Hum Cell. 1991 Mar;4(1):33-7. Japanese. PubMed PMID: 1888702.

168: Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci. 1991 Mar;98 ( Pt 3):317-22. PubMed PMID: 1676033.

169: Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M, Saijo N. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer. 1991 Feb;63(2):237-41. PubMed PMID: 1997100; PubMed Central PMCID: PMC1971793.

170: Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):287-9. PubMed PMID: 1991690.

171: Basu A, Lazo JS. Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum(II) resistance by v-mos. Cancer Res. 1991 Feb 1;51(3):893-6. PubMed PMID: 1824827.

172: Takada Y, Greig NH, Vistica DT, Rapoport SI, Smith QR. Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier. Cancer Chemother Pharmacol. 1991;29(2):89-94. Erratum in: Cancer Chemother Pharmacol 1992;30(2):164. PubMed PMID: 1760863.

173: Tsakanikas S, Papanastasiou K, Stamatelou M, Maniatis A. Intermediate dose of intravenous melphalan in advanced multiple myeloma. Oncology. 1991;48(5):369-71. PubMed PMID: 1745483.

174: Barranco SC, Townsend CM Jr, Weintraub B, Beasley EG, MacLean KK, Shaeffer J, Liu NH, Schellenberg K. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro. Cancer Res. 1990 Jun 15;50(12):3614-8. PubMed PMID: 2340510.

175: Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990 Jun 1;50(11):3339-44. PubMed PMID: 2334928.

176: Arnould R, Dubois J, Abikhalil F, Libert A, Ghanem G, Atassi G, Hanocq M, Lejeune FJ. Compared cytotoxicity effects of five anticancer drugs on human (HBL) and mouse (B16) melanoma cells in vitro. Anticancer Res. 1990 May-Jun;10(3):789-93. PubMed PMID: 2369092.

177: Puchalski RB, Fahl WE. Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2443-7. PubMed PMID: 2320566; PubMed Central PMCID: PMC53705.

178: Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J, Muramatsu M, Sato K, Terada M, Tew KD. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem. 1990 Mar 15;265(8):4296-301. PubMed PMID: 2407735.

179: Meunier F, van der Auwera P, Aoun M, Piccart M, Sculier JP. Therapy of infections related to intraperitoneal catheters in patients with ovarian cancer. Scand J Infect Dis Suppl. 1990;72:26-8. PubMed PMID: 2151063.

180: Klenner T, Berger MR, Zelezny O, Fink M, Schmähl D. Antineoplastic efficacy of melphalan and N-(2-chloroethyl)-N-nitrosocarbamoyl-omega-lysine, in combination with diazoxide or insulin in autochthonous mammary carcinoma of the Sprague-Dawley rat. J Cancer Res Clin Oncol. 1990;116(1):45-50. PubMed PMID: 2107182.

181: Cole SP. Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother Pharmacol. 1990;26(4):250-6. PubMed PMID: 1973363.

182: Saburi Y, Nakagawa M, Ono M, Sakai M, Muramatsu M, Kohno K, Kuwano M. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res. 1989 Dec 15;49(24 Pt 1):7020-5. PubMed PMID: 2479474.

183: Zylicz Z, Hofs HP, Wagener DJ, Van Rennes H, Wessels JM, van den Broek LA, Ottenheijm HC. Modulation of the in vitro cytotoxicity of seven anticancer drugs by protein synthesis inhibition using sparsomycin. Anticancer Res. 1989 Nov-Dec;9(6):1835-40. PubMed PMID: 2483308.

184: Fujii T, Niimura K, Furusho T, Sugita N, Oikawa M, Takahashi N, Yoshimura M, Oguchi Y, Iijima H, Matsunaga K, et al. Mechanism of action of the antitumour effect of K18. J Int Med Res. 1989 Mar-Apr;17(2):132-40. PubMed PMID: 2721813.

185: Mamuris Z, Prieur M, Dutrillaux B, Aurias A. The chemotherapeutic drug melphalan induces breakage of chromosomes regions rearranged in secondary leukemia. Cancer Genet Cytogenet. 1989 Jan;37(1):65-77. PubMed PMID: 2917334.

186: Houghton PJ, Houghton JA, Myers L, Cheshire P, Howbert JJ, Grindey GB. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol. 1989;25(2):84-8. PubMed PMID: 2598403.

187: Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol. 1988 Dec 15;37(24):4727-33. PubMed PMID: 2462423.

188: Mochizuki K. [Anticancer drug screening test for human osteosarcoma transplanted into nude mice]. Nippon Seikeigeka Gakkai Zasshi. 1988 Nov;62(11):991-1001. Japanese. PubMed PMID: 3249094.

189: Gupta RS, Murray W, Gupta R. Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line. Br J Cancer. 1988 Oct;58(4):441-7. PubMed PMID: 3207599; PubMed Central PMCID: PMC2246790.

190: Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988 Sep 30;241(4874):1813-5. PubMed PMID: 3175622.

191: Wingen F, Pool BL, Klein P, Klenner T, Schmähl D. Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat--benefit of combining bisphosphonates with cytostatic agents. Invest New Drugs. 1988 Sep;6(3):155-67. PubMed PMID: 3056867.

192: Horowitz ME, Etcubanas E, Christensen ML, Houghton JA, George SL, Green AA, Houghton PJ. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol. 1988 Feb;6(2):308-14. PubMed PMID: 3276826.

193: Soble MJ, Dorr RT. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice. Anticancer Res. 1988 Jan-Feb;8(1):17-22. PubMed PMID: 3358633.

194: Greig NH, Sweeney DJ, Rapoport SI. Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. Cancer Chemother Pharmacol. 1988;21(1):1-8. PubMed PMID: 3342460.

195: Teicher BA, McIntosh-Lowe NL, Rose CM. Effect of various oxygenation conditions and fluosol-DA on cancer chemotherapeutic agents. Biomater Artif Cells Artif Organs. 1988;16(1-3):533-46. PubMed PMID: 2460166.

196: Ahmann FR, Garewal HS, Schifman R, Celniker A, Rodney S. Intracellular adenosine triphosphate as a measure of human tumor cell viability and drug modulated growth. In Vitro Cell Dev Biol. 1987 Jul;23(7):474-80. PubMed PMID: 3610945.

197: Jordan J, d'Arcy Doherty M, Cohen GM. Effects of glutathione depletion on the cytotoxicity of agents toward a human colonic tumour cell line. Br J Cancer. 1987 Jun;55(6):627-31. PubMed PMID: 3620304; PubMed Central PMCID: PMC2002042.

198: Ishioka C, Kanamaru R, Sato T, Konishi Y, Himori T, Mimata Y, Wakui A. [A case of multiple myeloma responding very well to the combination of K18 with prednisolone]. Gan To Kagaku Ryoho. 1987 Apr;14(4):1164-6. Japanese. PubMed PMID: 2436580.

199: Yamamoto S, Tanaka H, Namba M. [Potentiation of the cytotoxic effects of anticancer drugs on human genitourinary neoplastic cells by recombinant gamma-interferon]. Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 1):699-705. Japanese. PubMed PMID: 3103539.

200: Soble MJ, Dorr RT. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):161-80. PubMed PMID: 3823607.

201: Tsay BL, Wolfinbarger L Jr. Phase I study of beta-alanyl-melphalan as a potent anticancer drug. Cancer Chemother Pharmacol. 1987;19(3):190-6. PubMed PMID: 3581413.

202: Ben-Efraim S, Gal T, Zimber C, Weiss DW. Classification of cancer chemotherapeutic drugs according to their ability to potentiate contact sensitivity to dinitrofluorobenzene. Anticancer Res. 1986 Nov-Dec;6(6):1341-5. PubMed PMID: 3492958.

203: McMillan TJ, Hart IR. Enhanced experimental metastatic capacity of a murine melanoma following pre-treatment with anticancer drugs. Clin Exp Metastasis. 1986 Oct-Dec;4(4):285-92. PubMed PMID: 2431822.

204: Ben-Efraim S, Shoval S, Gal T, Ophir R. Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity. Anticancer Res. 1986 Jul-Aug;6(4):801-5. PubMed PMID: 2944475.

205: Hildebrand-Zanki SU, Kern DH. A rapid bioassay to determine stabilities of anticancer agents under conditions of the clonogenic assay. In Vitro Cell Dev Biol. 1986 May;22(5):247-52. PubMed PMID: 3710996.

206: Cantrell JE Jr, Green D, Schein PS. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice. Cancer Res. 1986 May;46(5):2340-3. PubMed PMID: 2938728.

207: Floersheim GL, Bieri A, Chiodetti N. Xenografts in pharmacologically immunosuppressed mice as a model to test the chemotherapeutic sensitivity of human tumors. Int J Cancer. 1986 Jan 15;37(1):109-14. PubMed PMID: 3455687.

208: Dorr RT, Alberts DS, Soble M. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemother Pharmacol. 1986;16(2):91-4. PubMed PMID: 3948308.

209: Lockshin A, Giovanella BC, Stehlin JS Jr. Quantitative evaluation of anticancer agents against human melanoma cells implanted in nude mice. Exp Cell Biol. 1986;54(3):149-54. PubMed PMID: 3743866.

210: Bhuyan BK, Badiner GJ, Adams EG, Chase R. Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture. Invest New Drugs. 1986;4(4):315-23. PubMed PMID: 3473056.

211: Fry DW, Jackson RC. Membrane transport alterations as a mechanism of resistance to anticancer agents. Cancer Surv. 1986;5(1):47-79. Review. PubMed PMID: 3297313.

212: Ben-Efraim S, Shoval S, Ophir R. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma. Cancer Immunol Immunother. 1986;22(1):43-8. PubMed PMID: 2939947.

213: Takamizawa H, Sekiya S, Iwasawa H, Ishige H, Tokita H, Tanaka N. [A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect]. Gan To Kagaku Ryoho. 1985 Dec;12(12):2293-7. Japanese. PubMed PMID: 2416274.

214: Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol. 1985 Sep;12(3 Suppl 4):38-42. PubMed PMID: 3931226.

215: Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, Ozols RF. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 1985 May;45(5):2110-5. PubMed PMID: 3986765.

216: Greig NH, Sweeney DJ, Rapoport SI. Inability of dimethyl sulfoxide to increase brain uptake of water-soluble compounds: implications to chemotherapy for brain tumors. Cancer Treat Rep. 1985 Mar;69(3):305-12. PubMed PMID: 3978658.

217: Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y, Saijo N. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol. 1985;14(2):104-7. PubMed PMID: 3971474.

218: Jones SE, Dean JC, Young LA, Salmon SE. The human tumor clonogenic assay in human breast cancer. J Clin Oncol. 1985 Jan;3(1):92-7. PubMed PMID: 3965634.

219: Kanzawa F, Matsushima Y, Hoshi A, Shimizu E, Saijo N, Miyazawa N. Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay. Invest New Drugs. 1985;3(4):341-7. PubMed PMID: 3003004.

220: Umbach GE, Singletary SE, Tomasovic B, Spitzer G, Hug V, Drewinko B. Dose-survival curves of cis-platinum, melphalan, and velban in human granulocyte/macrophage progenitor cells. Int J Cell Cloning. 1984 Nov;2(6):335-40. PubMed PMID: 6542929.

221: Valeriote F, Medoff G, Tolen S, Dieckman J. Amphotericin B potentiation of the cytotoxicity of anticancer agents against both normal hematopoietic and leukemia cells in mice. J Natl Cancer Inst. 1984 Aug;73(2):475-82. PubMed PMID: 6589439.

222: Rieche K. Carcinogenicity of antineoplastic agents in man. Cancer Treat Rev. 1984 Mar;11(1):39-67. Review. PubMed PMID: 6375862.

223: Eksborg S, Ehrsson H. Liquid chromatography in anticancer drug research with special reference to anthraquinone glycosides. J Pharm Biomed Anal. 1984;2(2):297-303. PubMed PMID: 16867757.

224: Greig N, Newell D, Hellmann K. Metrazol enhances brain penetration and therapeutic efficacy of some anticancer agents: implications for brain metastases. Clin Exp Metastasis. 1984 Jan-Mar;2(1):55-9. PubMed PMID: 6543690.

225: Giovanella BC, Stehlin JS Jr, Shepard RC, Williams LJ Jr. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer. 1983 Oct 1;52(7):1146-52. PubMed PMID: 6883283.

226: Yamamoto S, Tanaka H, Kanamori T, Nobuhara M, Namba M. In vitro studies on potentiation of cytotoxic effects of anticancer drugs by interferon on a human neoplastic cell line (HeLa). Cancer Lett. 1983 Sep;20(2):131-8. PubMed PMID: 6199106.

227: Namba M, Yamamoto S, Tanaka H, Kanamori T, Nobuhara M, Kimoto T. [Potentiation of the cytotoxic effects of various anticancer drugs by interferon on human neoplastic cells (HeLa) in culture]. Gan To Kagaku Ryoho. 1983 May;10(5):1308-12. Japanese. PubMed PMID: 6191681.

228: Barranco SC, Townsend CM Jr, Quraishi MA, Burger NL, Nevill HC, Howell KH, Boerwinkle WR. Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs. Invest New Drugs. 1983;1(2):117-27. PubMed PMID: 6678861.

229: Davis TP, Peng YM, Goodman GE, Alberts DS. HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. J Chromatogr Sci. 1982 Nov;20(11):511-6. PubMed PMID: 6960001.

230: Valeriote F, Lynch R, Berger NA, White E, Coulter D. Growth characteristics of MOPC-315 plasmacytoma and response to anticancer agents. J Natl Cancer Inst. 1981 Jun;66(6):1083-8. PubMed PMID: 7017213.

231: Taetle R, Koessler AK, Howel SB. In vitro growth and drug sensitivity of tumor colony-forming units from human tumor xenografts. Cancer Res. 1981 May;41(5):1856-60. PubMed PMID: 7214353.

232: Alberts DS, Chen HG, Benz D, Mason NL. Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Br J Cancer. 1981 Mar;43(3):330-4. PubMed PMID: 7225283; PubMed Central PMCID: PMC2010602.

233: Alberts DS, Chen HS, Salmon SE, Surwit EA, Young L, Moon TE, Meyskens FL Jr. Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. Cancer Chemother Pharmacol. 1981;6(3):279-85. PubMed PMID: 6172215.

234: Meyn RE, Meistrich ML, White RA. Cycle-dependent anticancer drug cytotoxicity in mammalian cells synchronized by centrifugal elutriation. J Natl Cancer Inst. 1980 May;64(5):1215-9. PubMed PMID: 6154171.

235: Berstock DA, Houghton J, Bennett A. Improved anticancer effect by combining cytotoxic drugs with an inhibitor of prostaglandin synthesis. Adv Prostaglandin Thromboxane Res. 1980;6:567-9. PubMed PMID: 7386289.

236: Hill DL, Montgomery JA. Selective uptake and retention of anticancer agents by sensitive cells. Cancer Chemother Pharmacol. 1980;4(4):221-5. Review. PubMed PMID: 6449312.

237: Chen HS, Gross JF. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep. 1980 Jan;64(1):31-40. PubMed PMID: 6155210.

238: Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459-73. PubMed PMID: 291480.

239: Berstock DA, Houghton J, Bennett A. Improved anticancer effect by combining cytotoxic drugs with an inhibitor of prostaglandin synthesis. Cancer Treat Rev. 1979 Jun;6 Suppl:69-71. PubMed PMID: 115588.

240: Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med. 1978 Jun 15;298(24):1321-7. PubMed PMID: 77475.

241: Ovejera AA, Houchens DP, Barker AD. Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci. 1978 Jan-Feb;8(1):50-6. PubMed PMID: 623430.

242: Schabel FM Jr, Trader MW, Laster WR Jr, Wheeler GP, Witt MH. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother. 1978;23:200-15. Review. PubMed PMID: 348078.

243: Morasca L, Balconi G, Erba E, Cvitkovic E. Studies on the sensitivity of anticancer agents of normal human cells in culture. Adv Exp Med Biol. 1975;53:511-9. PubMed PMID: 1121934.

244: Everett J. Walker carcinosarcoma 256 in study of anticancer agents. II. Results. Cancer Res. 1966 Aug;26(8 Pt 2):942-9. PubMed PMID: 4224206.

245: KNOCK FE. NEWER ANTICANCER AGENTS. Med Clin North Am. 1964 Mar;48:501-27. Review. PubMed PMID: 14151253.

246: STALEY CJ, KUKRAL JC, PRESTON FW. Effect of anticancer drugs on experimental wound healing. Surg Forum. 1962;13:35-6. PubMed PMID: 13983304.